Clinical Evaluation for Sarcoma Originated From Bone

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2019-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating primary sarcoma originated from bone treated with chemotherapy or targeted therapy, which did not have the definition of measurement methods either. This study evaluates whether clinical imaging findings of sarcoma after preoperative chemotherapy correlate with tumor responses by pathological evaluation by Huvos classifications and develops reliable, quantitative, clinical response criteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Osteosarcoma Biobank in Peking University People's Hospital

NCT03362086

Osteosarcoma

UNKNOWN

Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma

NCT05194605

Osteosarcoma

UNKNOWN

Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors

NCT07112989

Bone and Soft Tissue Tumors Bone Metastases From Solid Tumors Lung Metastases

RECRUITING

CTC in Lung Caner Patients With Bone Metastases

NCT04568291

Lung Cancer Bone Metastases Single Cell Sequencing Technology

UNKNOWN NA

PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy

NCT02035683

Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Stage IIIB

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 1570 lesions were evaluated by clinical imaging including X-ray, computed tomography, magnetic resonance imaging and bone scan or PET/CT preoperatively treated with chemotherapy. All patients had surgery in our center and get pathological evaluation by tumor necrosis rate. Statistical diversity analysis was performed by different pathological groups and Receiver Operating Characteristic Curves，ROC were done to find the dividing clinical parameters (Cut-off values) to distinguish different pathological groups.The cut-off values of change rate of maximum diameters of tumor located in extremities were 86%, 50.7% and 0.02% for Huvos Ⅳ,Ⅲ,ⅡandⅠgroups. The differentiation was not obvious using bone scan to distinguish different pathological responses. And the cut-off value for SUVmax value for Huvos Ⅲ,ⅡandⅠgroups were 60.7% and 31.4%.After Multidisciplinary discussion in multiple sites of China, we finally designed a evaluation system based on our data. This study is desgined to prospectively compare the sensitivity and specificity of this Clinical evaluation of primary sarcoma originated from bone with other clinical evaluation system,such as RECIST 1.1, Choi and PERCIST.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sensitivity Specificity Histological Response Survival

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) histologically confirmed high-grade osteosarcoma;
* 2\) initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital, Xijing Hospital or The Second Hospital affiliated to Zhejiang Hospital;
* 3\) imaging evaluation should be available;
* 4\) completed neo-adjuvant chemotherapy and at least 8 cycles of adjuvant chemotherapy;
* 5\) expected to live longer than 3 months with Eastern Cooperative Oncology Group performance status of 0 or 1;
* 6\) acceptable hematologic, hepatic, and renal function.